The analyst upgraded the rating of Modena's stock to "outperform the market" and set the target stock price at $142 per share. This reflects greater confidence in the company's growth potential. Analysts are encouraged by Moderna's product releases in the next 12 to 18 months and believe that these products will increase sales in 2025 and have positive expectations for pipelines.